MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 530959 | Name: KBP-7018

Description:

WARNING: This product is for research use only, not for human or veterinary use.

KBP-7018 is a novel, tyrosine kinase-selective inhibitor with potent effects on three fibrotic kinases (c-KIT, PDGFR, and RET). It IC50 values are: c-KIT 10nM; RET 7.6 nM; PDGFR 25nM. KBP-7018 represents a novel multikinase inhibitor with differentiated activity, highly enhanced selectivity, and acceptable PK profiles that will enter phase I clinical trials.

Chemical Structure

KBP-7018
KBP-7018
CAS#1613437-66-3 (free base)

Theoretical Analysis

MedKoo Cat#: 530959

Name: KBP-7018

CAS#: 1613437-66-3 (free base)

Chemical Formula: C31H30N4O5

Exact Mass: 538.2216

Molecular Weight: 538.60

Elemental Analysis: C, 69.13; H, 5.61; N, 10.40; O, 14.85

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
1613437-67-4 (HCl) 1613437-66-3 (free base)
Synonym
KBP-7018; KBP 7018; KBP7018.
IUPAC/Chemical Name
methyl (Z)-3-(((1-(2-morpholinoacetyl)indolin-5-yl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxylate
InChi Key
JVDJHTYIWQIOCA-ZIADKAODSA-N
InChi Code
InChI=1S/C31H30N4O5/c1-39-31(38)22-7-9-24-25(18-22)33-30(37)28(24)29(20-5-3-2-4-6-20)32-23-8-10-26-21(17-23)11-12-35(26)27(36)19-34-13-15-40-16-14-34/h2-10,17-18,32H,11-16,19H2,1H3,(H,33,37)/b29-28-
SMILES Code
O=C(OC)C1=CC=C2C(NC(/C2=C(NC3=CC=C(N(C(CN4CCOCC4)=O)CC5)C5=C3)/C6=CC=CC=C6)=O)=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Idiopathic pulmonary fibrosis (IPF) is a serious and deadly disease for which treatment options are limited. The recent approval of antifibrosis agent nintedanib represents one of the first therapeutic approaches for the treatment of IPF.

Preparing Stock Solutions

The following data is based on the product molecular weight 538.60 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1. Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis Zhenhua Huang, Heran Li, Qian Zhang, Fangzheng Lu, Mei Hong, Zhigang Zhang, Xiaocui Guo, Yuanju Zhu, Sanming Li, and Hongzhuo Liu Publication Date (Web): September 30, 2017 (Letter) DOI: 10.1021/acsmedchemlett.7b00164 2: Huang Z, Li H, Zhang Q, Tan X, Lu F, Liu H, Li S. Characterization of preclinical in vitro and in vivo pharmacokinetics properties for KBP-7018, a new tyrosine kinase inhibitor candidate for treatment of idiopathic pulmonary fibrosis. Drug Des Devel Ther. 2015 Aug 5;9:4319-28. doi: 10.2147/DDDT.S83055. eCollection 2015. PubMed PMID: 26273193; PubMed Central PMCID: PMC4532346.